PRESS RELEASE

Munich, 6 May 2022

Under the direction of Dr. Thomas Grädler and Peter Kipp, honert provided comprehensive tax and legal advice to the multinational founders of OmicEra Diagnostics GmbH on the sale of their shareholdings to a subsidiary of Exact Sciences Corporation, which specializes in molecular diagnostic cancer detection and is traded on NASDAQ under EXAS.

OmicEra Diagnostics was also founded under the advice of honert at the end of 2019. OmicEra Diagnostics is a biotech specialist in the field of large-scale protein analysis and proteomics. Using mass spectrometry and artificial intelligence, large volumes of clinical samples are analyzed with regard to cell proteins for medical diagnosis. The range of services offered by the emerging market leader OmicEra Diagnostics includes a high degree of automation of the analysis procedures as well as the development of novel biomarkers and software components for real-time monitoring and evaluation of high-performance liquid chromatography and mass spectrometry procedures.

Advisors of founders of OmiCera Diagnostics GmbH:

honert münchen PartG mbB: Dr. Thomas Grädler (lead partner / M&A / corporate law / tax law), Peter Kipp (M&A / corporate law)